Joint (NASDAQ:JYNT) Stock Rating Lowered by Zacks Research

Joint (NASDAQ:JYNT) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Joint in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Joint currently has an average rating of “Hold” and a consensus price target of $17.00.

Joint Price Performance

JYNT opened at $8.98 on Monday. The business’s 50-day moving average price is $8.77 and its two-hundred day moving average price is $8.80. Joint has a 1 year low of $7.50 and a 1 year high of $13.47. The company has a market capitalization of $128.59 million, a price-to-earnings ratio of 47.27 and a beta of 1.22.

Joint (NASDAQ:JYNT) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.02. The firm had revenue of $15.17 million for the quarter, compared to the consensus estimate of $14.12 million. Joint had a negative return on equity of 1.28% and a net margin of 4.99%. Sell-side analysts anticipate that Joint will post 0.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Joint

In related news, major shareholder Charles E. Jobson acquired 16,753 shares of the firm’s stock in a transaction dated Friday, January 23rd. The stock was bought at an average price of $10.00 per share, for a total transaction of $167,530.00. Following the acquisition, the insider directly owned 1,638,424 shares of the company’s stock, valued at approximately $16,384,240. The trade was a 1.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders bought 32,598 shares of company stock valued at $302,302. 27.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Joint

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in Joint during the fourth quarter worth about $124,000. Clayton Partners LLC bought a new position in Joint during the fourth quarter worth about $1,652,000. Price T Rowe Associates Inc. MD grew its holdings in Joint by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 26,504 shares of the company’s stock worth $232,000 after purchasing an additional 5,800 shares during the period. Russell Investments Group Ltd. grew its holdings in Joint by 77.3% during the fourth quarter. Russell Investments Group Ltd. now owns 205,411 shares of the company’s stock worth $1,791,000 after purchasing an additional 89,526 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Joint during the fourth quarter worth about $766,000. Institutional investors own 76.88% of the company’s stock.

About Joint

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.